| INTIBIA Pivotal Study (NCT05250908) | Coloplast A/S | 2022-03-07 |
| Infectious Complications After Cystectomy: A Prospective Observational Study (NCT05153694) | Ludwig-Maximilians - University of Munich | 2021-12-01 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (NCT04922047) | RenJi Hospital | 2021-06-01 |
| Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH) (NCT04161716) | BioSerenity | 2020-07-07 |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy (NCT04442724) | Cedars-Sinai Medical Center | 2020-07-01 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (NCT03081858) | Lipac Oncology LLC | 2018-05-17 |
| Falls and Balance of Patients With Parkinson's Disease With Urinary Disturbance (NCT03845725) | Ordu University | 2018-02-01 |
| Pediatric Urology Recovery After Surgery Endeavor (PURSUE) (NCT03245242) | Washington University School of Medicine | 2017-04-01 |
| Eosinophilic Cystitis Mimicking Urothelial Neoplasia (NCT04914442) | Al-Azhar University | 2017-01-17 |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (NCT02386072) | Astellas Scientific & Medical Affairs, Inc. | 2015-01-05 |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients (NCT02307487) | UroGen Pharma Ltd. | 2014-12-01 |
| A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (NCT02320773) | Astellas Pharma Europe Ltd. | 2014-11-25 |
| Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (NCT01930799) | Allergan | 2013-08-01 |
| A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (NCT01908829) | Astellas Pharma Europe Ltd. | 2013-07-10 |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients (NCT02891460) | UroGen Pharma Ltd. | 2013-01-01 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (NCT01340027) | Astellas Pharma Europe B.V. | 2011-03-29 |
| A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain (NCT01060254) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-04-06 |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer (NCT00384891) | Medical Enterprises Europe B.V. | 2002-02-01 |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (NCT02254915) | Medical Enterprises Europe B.V. | |